Mico BioMed Co. Ltd. Cash Flow Conversion Efficiency
Mico BioMed Co. Ltd. cash flow conversion efficiency. Based on the latest financial reports, Mico BioMed Co. Ltd. (214610) has a cash flow conversion efficiency ratio of -0.315x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-8.13 Billion ≈ $-5.51 Million USD) by net assets (₩25.81 Billion ≈ $17.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Mico BioMed Co. Ltd. (2016–2024)
Cash flow conversion efficiency of Mico BioMed Co. Ltd. from 2016 to 2024. This chart illustrates how Mico BioMed Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View 214610 stock price for real-time trading data and today's change.
Mico BioMed Co. Ltd. Cash Flow Conversion Ratio Explained
Mico BioMed Co. Ltd. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mico BioMed Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mico BioMed Co. Ltd. ranked by their cash flow conversion efficiency. Also see 214610 company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Imexhs Ltd
AU:IME
|
-0.103x |
|
Nafpaktos Textile Industry S.A
AT:NAYP
|
0.024x |
|
Moleculin Biotech Inc
NASDAQ:MBRX
|
-0.358x |
|
Park Ha Biological Technology Co., Ltd.
NASDAQ:PHH
|
-12.940x |
|
Ruchi Infrastructure Limited
NSE:RUCHINFRA
|
0.089x |
|
Wintao Communications Co. Ltd
SHE:301139
|
0.002x |
|
Hang Feng Technology Innovation Co., Ltd.
NASDAQ:FOFO
|
N/A |
|
HK Co. Ltd
KQ:044780
|
0.021x |
Annual Cash Flow Conversion Efficiency for Mico BioMed Co. Ltd. (2016–2024)
The table below shows the annual cash flow conversion efficiency of Mico BioMed Co. Ltd. from 2016 to 2024. Review 214610 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩25.89 Billion ≈ $17.54 Million |
₩-10.70 Billion ≈ $-7.25 Million |
-0.413x | -32.16% |
| 2023-12-31 | ₩36.33 Billion ≈ $24.62 Million |
₩-11.36 Billion ≈ $-7.70 Million |
-0.313x | +60.50% |
| 2022-12-31 | ₩17.69 Billion ≈ $11.99 Million |
₩-14.01 Billion ≈ $-9.49 Million |
-0.792x | -381.03% |
| 2021-12-31 | ₩52.26 Billion ≈ $35.42 Million |
₩-8.60 Billion ≈ $-5.83 Million |
-0.165x | +50.70% |
| 2020-12-31 | ₩55.96 Billion ≈ $37.92 Million |
₩-18.68 Billion ≈ $-12.66 Million |
-0.334x | +96.73% |
| 2019-12-31 | ₩1.02 Billion ≈ $691.72K |
₩-10.43 Billion ≈ $-7.07 Million |
-10.223x | -759.39% |
| 2018-12-31 | ₩5.71 Billion ≈ $3.87 Million |
₩-6.79 Billion ≈ $-4.60 Million |
-1.190x | -40.61% |
| 2017-12-31 | ₩3.42 Billion ≈ $2.32 Million |
₩-2.89 Billion ≈ $-1.96 Million |
-0.846x | +18.99% |
| 2016-12-31 | ₩3.83 Billion ≈ $2.59 Million |
₩-3.99 Billion ≈ $-2.71 Million |
-1.044x | -- |
About Mico BioMed Co. Ltd.
RollingStone Co., Ltd. provides point-of-care-testing diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real… Read more